中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载：104/0  |  提交时间：2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China 期刊论文
CANCER MANAGEMENT AND RESEARCH, 2019, 卷号: 11, 期号: 无, 页码: 1473-1492
作者:  Wu, Haibo;  Wang, Wei;  Du, Jun;  Li, Hong;  Wang, Huogang;  Huang, Liangliang;  Xiang, Hang;  Xie, Jing;  Liu, Xiaoli;  Li, Heng;  Lin, Wenchu
浏览  |  Adobe PDF(1845Kb)  |  收藏  |  浏览/下载：194/161  |  提交时间：2020/05/21
breast cancer  PIK3CA  clinicopathological characteristics  prognosis